Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973)
The incidence of urothelial bladder cancer (UBC) has increased during the last decades; in western countries, it is the fourth most common tumor type, after prostate, lung, and colorectal cancer [1]. UBC has a worldwide incidence of 294,345, and 88,315 cases per year in men and women (European prevalence of 112,819, and 30,736 cases, respectively).
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Jos é Antonio March-Villalba, David Ramos-Soler, Pilar Soriano-Sarrió, David Hervás-Marín, Laura Martínez-García, José María Martínez-Jabaloyas Tags: Original Article Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Colorectal Cancer | Urology & Nephrology | Women